OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
Featured Reports
2017 Annual Report on Form 10-K - PDF 2017 Annual Report on Form 10-K
Fact Sheet - PDF Fact Sheet
OSUR (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.24 (2.04%)
Data as of 02/21/19 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
02/06/19OraSure Announces 2018 Full Year and Fourth Quarter Financial Results
BETHLEHEM, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the full year and fourth quarter of 2018. Financial Highlights Net revenues for the year ended December 31, 2018 were $181.7 million, a 9% increase from 2017.  Net product revenues were $165.4 million, representing 2% growth over 2017. Net revenues for the fourth quarter ... 
Printer Friendly Version
01/10/19OraSure Technologies Earnings Conference Call Invitation
2018 Fourth Quarter Earnings Conference Call Wednesday, February 6, 2019, 5:00 p.m. ET BETHLEHEM, Pa., Jan. 10, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2018 fourth quarter financial results, 2019 first quarter financial guidance and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 6, 2019.     February 6, 2019 Schedule         ... 
Printer Friendly Version
01/04/19OraSure Technologies, Inc. Announces Two Acquisitions and Reaffirms Fourth Quarter 2018 Guidance
CoreBiome leverages OraSure’s leadership position in microbiome sample collection with end-to-end laboratory services for sample processing, sequencing, and bioinformatics Novosanis’ urine collection technology expands molecular collection portfolio and advances OraSure’s expertise in non-invasive sampling BETHLEHEM, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, t... 
Printer Friendly Version
01/02/19OraSure Technologies, Inc.: Updated Release to Clarify Timing of Presentation
OraSure Technologies to Present at the 37th Annual J.P. Morgan Healthcare Conference BETHLEHEM, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 37TH Annual J.P. Morgan Healthcare Conference.  The conference will be simultaneously webcast over the Internet. Dr. Tang is schedule... 
Printer Friendly Version
Upcoming EventsMore >>
05/21/19 10:00 a.m. ET
OraSure Technologies, Inc. 2019 Annual Meeting of Stockholders
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet